Dose-modified R-CODOX-M / R-IVAC: high-risk reference without proven CNS disease (eviQ 4489/4490)
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
Registro de base de conocimiento para la auditoría. Contenido clínico provisional: esto no es una prescripción. Un oncólogo debe verificar fuentes originales, aplicabilidad y estado de revisión.
Fuente YAML: registro completo
| Componentes | Ninguna declarada |
|---|
| ID | REG-CODOX-M-IVAC |
|---|---|
| Tipo | Esquema terapéutico |
| Situación | pending_clinical_signoff |
| Enfermedades | Ninguna declarada |
| Fuentes | SRC-EVIQ-BURKITT-CODOX-4489 SRC-EVIQ-BURKITT-IVAC-4490 SRC-EVIQ-BURKITT-OVERVIEW-3727 SRC-EVIQ-CODOX-PATIENT-4489 SRC-EVIQ-IVAC-PATIENT-4490 SRC-EVIQ-MOUTH-PATIENT-3099 SRC-EVIQ-TLS-108 SRC-NCCN-BCELL-2025 |
Notas
Scoped reference schedule repair based on eviQ 4489 v1 and 4490 v2, for high-risk Burkitt WITHOUT proven CNS disease. This is not original Magrath or LMB and not a universal Burkitt/CNS prescription. The indication now requires explicit high-risk and CNS-negative confirmation. Risk classification, broader eligibility, ranking and other protocol variants still require separate audits. Age, fitness, efficacy, availability and patient watchpoints are not validated by this repair. Mesna schedules may vary by institution. Intrathecal procedures must remain separate from IV drug administration; vincristine must NEVER be administered intrathecally.
Utilizado por
Indicación
IND-BURKITT-1L-CODOXM-IVAC- IND-BURKITT-1L-CODOXM-IVAC
Seguimiento
MON-CODOX-IVAC-REGIMEN- Modified R-CODOX-M / R-IVAC block-specific reference monitoring